Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:5405810.
doi: 10.1155/2016/5405810. Epub 2016 Jun 29.

Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide

Hisao Imai  1 , Keita Mori  2 , Nodoka Watase  3 , Sakae Fujimoto  4 , Kyoichi Kaira  5 , Masanobu Yamada  6 , Koichi Minato  1
Affiliations

Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide

Hisao Imai et al. Can Respir J. 2016.

Abstract

Background. The effects of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with small-cell lung cancer (SCLC). Therefore, by using individual-level data, we aimed to determine the relationships between progression-free survival (PFS) or postprogression survival (PPS) and OS after first-line chemotherapies in patients with extensive disease-SCLC (ED-SCLC) treated with carboplatin plus etoposide. Methods. Between July 1998 and December 2014, we analyzed 63 cases of patients with ED-SCLC who were treated with carboplatin and etoposide as first-line chemotherapy. The relationships of PFS and PPS with OS were analyzed at the individual level. Results. Spearman rank correlation analysis and linear regression analysis showed that PPS was strongly correlated with OS (r = 0.90, p < 0.05, and R (2) = 0.71) and PFS was moderately correlated with OS (r = 0.72, p < 0.05, and R (2) = 0.62). Type of relapse (refractory/sensitive) and the number of regimens administered after disease progression after the first-line chemotherapy were both significantly associated with PPS (p < 0.05). Conclusions. PPS has a stronger relationship with OS than does PFS in ED-SCLC patients who have received first-line chemotherapy. These results suggest that treatments administered after first-line chemotherapy affect the OS of ED-SCLC patients treated with carboplatin plus etoposide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Kaplan-Meier plots showing progression-free survival (PFS). Median progression-free survival: 4.1 months. #Outlier of one case exists. (b) Kaplan-Meier plots showing overall survival (OS). Median overall survival: 8.2 months.
Figure 2
Figure 2
(a) Correlation between overall survival (OS) and progression-free survival (PFS). (b) Correlation between overall survival (OS) and postprogression survival (PPS). ∗The  r values represent Spearman's rank correlation coefficient. ∗∗The  R 2 values represent linear regression.
Figure 3
Figure 3
Progression-free survival (PFS) and postprogression survival (PPS) in the overall population.
Figure 4
Figure 4
(a) Kaplan-Meier plots showing postprogression survival (PPS), according to the type of relapse. Refractory relapse, median = 3.3 months; sensitive relapse, median = 10.0 months. (b) Kaplan-Meier plots showing postprogression survival (PPS), according to the number of regimens after progression. No further regimen, median = 0.8 months; 1 regimen, median = 4.8 months; ≥2 regimens, median = 9.5 months.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2012;62(1):10–29. doi: 10.3322/caac.20138. - DOI - PubMed
    1. Govindan R., Page N., Morgensztern D., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. Journal of Clinical Oncology. 2006;24(28):4539–4544. doi: 10.1200/jco.2005.04.4859. - DOI - PubMed
    1. Shepherd F. A., Crowley J., Van Houtte P., et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. Journal of Thoracic Oncology. 2007;2(12):1067–1077. doi: 10.1097/jto.0b013e31815bdc0d. - DOI - PubMed
    1. Johnson B. E., Jänne P. A. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematology/Oncology Clinics of North America. 2004;18(2):309–322. doi: 10.1016/j.hoc.2003.12.008. - DOI - PubMed
    1. Demedts I. K., Vermaelen K. Y., van Meerbeeck J. P. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. European Respiratory Journal. 2010;35(1):202–215. doi: 10.1183/09031936.00105009. - DOI - PubMed

LinkOut - more resources